The Chinese Journal of Clinical Pharmacology 2024;40(21):3186-3190

doi:10.13699/j.cnki.1001-6821.2024.21.024

Research status of circulating tumor DNA in colorectal cancer

Shao-bo MO 1 ; Yun FENG ; Jun-jie PENG ; Hai ZOU

Affiliations

+expand

Keywords

circulating tumor DNA; colorectal cancer; minimal residual disease; early diagnosis; treatment monitoring

Country

China

Language

Chinese

Abstract

Circulating tumor DNA(ctDNA)is emerging as a pivotal technology in the diagnosis and therapeutic management of colorectal cancer(CRC).Serving as a liquid biopsy biomarker,ctDNA offers genetic insights into tumors,encompassing mutations,methylation patterns,and more,thereby holding significant promise for early detection,treatment response monitoring,and prognostic evaluation.This review comprehensively outlines the research strides in ctDNA pertaining to CRC,encompassing early-stage screening and diagnosis,minimal residual disease surveillance,treatment response tracking and prognostic status.